Omeros Corp said on Monday
it will discontinue a trial studying its therapy to treat a type
of kidney disease after it failed to meet the main goal of the
late-stage study. (Reporting by.
(Reuters) - Omeros Corp said on Monday it will discontinue a trial studying its therapy to treat a type of kidney disease after it failed to meet the .
/PRNewswire/ The binge-eating disorder treatment market size is expected to increase by USD 578.04 million from 2022 to 2027, registering a CAGR of 7.26%,.